Semaglutide (Ozempic, Wegovy): Evidence and Safety
Semaglutide is a GLP-1 receptor agonist that slows stomach emptying and reduces appetite. It is FDA-approved, as Ozempic for type 2 diabetes and Wegovy for chronic weight management, on the strength of large randomized trials, the strongest human evidence base of any peptide covered on this page. It is prescription-only; the real risk in practice is compounded, gray-market “semaglutide” sold outside a licensed pharmacy, which has documented purity and dosing-error problems.
Understand the mechanism A GLP-1 receptor agonist: it mimics a gut hormone that slows stomach emptying, raises insulin release when blood sugar is high, and acts on brain appetite centers to reduce hunger.
This is a hormone-mimicking mechanism, not a stimulant-style appetite suppressant.
See what the trials actually showed FDA approval rests on large randomized controlled trials: the STEP program for weight management and the SUSTAIN program for type 2 diabetes, both multi-thousand-patient RCTs published in the New England Journal of Medicine and replicated across trials.
This is the strongest human evidence base of any peptide on this page.
Know what is and is not approved FDA-approved: Ozempic for type 2 diabetes, Wegovy for chronic weight management. Prescription-only, dispensed through a licensed pharmacy.
The approval is indication-specific and prescription-gated, not an over-the-counter or general-use approval.
Know where the real risk sits Documented side effects include nausea, GI upset, rare pancreatitis, and gallbladder issues, plus a boxed warning about thyroid C-cell tumors seen in rodent studies. The larger real-world risk is compounded or gray-market “semaglutide” sold outside the licensed pharmacy system, which the FDA has warned carries purity and dosing-error problems.
Sourcing, not the approved molecule itself, is where the practical danger concentrates.
Semaglutide's evidence base is the strongest of any peptide covered here.
View sources
Wilding et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), NEJM 2021
Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Editorial disclosure. This protocol is written and fact-checked by the YourProtocol editorial team directly from the primary sources cited below; it is not written or reviewed by any outside expert.
Is this for you
- Anyone trying to understand what Ozempic or Wegovy actually is and what the evidence shows
- Anyone comparing FDA-approved GLP-1 drugs to unregulated “research peptides”
- Patients or caregivers preparing questions for a prescriber
- Readers who want the approved-use boundary made explicit
Cautions
- Educational only, not medical advice; any decision to start, stop, or dose semaglutide belongs with a licensed prescriber.
- Compounded or gray-market “semaglutide” sold outside a licensed pharmacy has documented purity and dosing-error problems per FDA warnings.
- Boxed warning: thyroid C-cell tumors were seen in rodent studies; discuss personal risk factors with a prescriber.